MK-1942 / Merck (MSD) - LARVOL DELTA

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (clinicaltrials.gov) - P2 | N=99 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Phase classification: P2a/2b ➔ P2

Phase classification • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2 | N=99 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Phase classification: P2a ➔ P2

Phase classification • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (clinicaltrials.gov) - P2a/2b | N=99 | Terminated | Sponsor: Merck Sharp & Dohme LLC | N=408 ➔ 99 | Active, not recruiting ➔ Terminated; Voluntarily terminated due to benefit/risk assessment

Enrollment change • Trial termination • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a | N=99 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Jan 2024 ➔ Sep 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2024 ➔ Sep 2023; Voluntarily terminated due to benefit/risk assessment

Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (clinicaltrials.gov) - P2a/2b | N=408 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: May 2025 ➔ Sep 2023 | Trial primary completion date: May 2025 ➔ Sep 2023

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (clinicaltrials.gov) - P2a/2b | N=408 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (clinicaltrials.gov) - P2a/2b | N=408 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: May 2026 ➔ May 2025 | Trial primary completion date: May 2026 ➔ May 2025

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a | N=140 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Aug 2024 ➔ Jan 2024 | Trial primary completion date: Aug 2024 ➔ Jan 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a | N=140 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Sep 2023 ➔ Aug 2024 | Trial primary completion date: Sep 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (clinicaltrials.gov) - P2a/2b | N=408 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety Trial of MK-1942 in Participants with Alzheimer’s Disease dementia (MK-1942-008) Eficacia y seguridad del estudio MK-1942 en participantes con demencia por enfermedad de Alzheimer (MK-1942-008). (clinicaltrialsregister.eu) - P2 | N=408 | Ongoing | Sponsor: Merck Sharp & Dohme LLC

New P2 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1 | N=27 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a | N=140 | Recruiting | Sponsor: Merck Sharp & Dohme Corp. | Trial completion date: Aug 2024 ➔ Sep 2023 | Trial primary completion date: Aug 2024 ➔ Sep 2023

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a | N=140 | Recruiting | Sponsor: Merck Sharp & Dohme Corp. | Trial completion date: Nov 2023 ➔ Aug 2024 | Trial primary completion date: Nov 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Dec 2021 ➔ May 2022; Trial primary completion date: Dec 2021 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a; N=140; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Depression • Mood Disorders • Psychiatry

Novamind Partners with Merck for New Treatment-Resistant Depression Trial (Issuer Direct) - "Novamind Inc....is pleased to announce that its wholly-owned subsidiary, Cedar Clinical Research ('CCR') has been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co....The phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression...The clinical trial begins enrolling individuals in March 2021."

Enrollment status • Licensing / partnership • CNS Disorders • Depression

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alzheimer's Disease • CNS Disorders

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (clinicaltrials.gov) - P2a; N=140; Not yet recruiting; Sponsor: Merck Sharp & Dohme Corp.

Clinical • New P2a trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: May 2021 ➔ Sep 2021; Initiation date: Oct 2020 ➔ Feb 2021; Trial primary completion date: May 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Nov 2020 ➔ May 2021; Initiation date: Apr 2020 ➔ Oct 2020; Trial primary completion date: Nov 2020 ➔ May 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Merck Sharp & Dohme Corp.

Clinical • New P1 trial